CoChat
Sign Up
Cited by 16Pharmacovigilance and Adverse Drug ReactionsData-Driven Disease SurveillanceComplementary and Alternative Medicine Studies

A database of pediatric drug effects to evaluate ontogenic mechanisms from child growth and development

Open access
Giangreco, Nicholas P., Tatonetti, Nicholas P.·2022·Med
DOI 10.1016/j.medj.2022.06.001PMC PMC9378670
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Adverse drug effects (ADEs) in children are common and may result in disability and death, necessitating post-marketing monitoring of their use. Evaluating drug safety is especially challenging in children due to the processes of growth and maturation, which can alter how children respond to treatment. Current drug safety-signal-detection methods do not account for these dynamics. METHODS: We recently developed a method called disproportionality generalized additive models (dGAMs) to better identify safety signals for drugs across child-development stages. FINDINGS: We used dGAMs on a database of 264,453 pediatric adverse-event reports and found 19,438 ADEs signals associated with development and validated these signals against a small reference set of pediatric ADEs. Using our approach, we can hypothesize on the ontogenic dynamics of ADE signals, such as that montelukast-induced psychiatric disorders appear most significant in the second year of life. Additionally, we integrated pediatric enzyme expression data and found that pharmacogenes with dynamic childhood expression, such as CYP2C18 and CYP27B1, are associated with pediatric ADEs. CONCLUSIONS: We curated KidSIDES, a database of pediatric drug safety signals, for the research community and developed the Pediatric Drug Safety portal (PDSportal) to facilitate evaluation of drug safety signals across childhood growth and development. FUNDING: This study was supported by grants from the National Institutes of Health (NIH).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.medj.2022.06.001

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 50

  1. [1]Smyth RMD Adverse drug reactions in children--a systematic review. PLoS One 7, e24061 (2012). 22403604 PMC3293884
  2. [2]Impicciatore P Incidence of adverse drug reactions in paediatric in/out-patients: A systematic review and meta-analysis of prospective studies. Br. J. Clin. Pharmacol 52, 77– 83 (2001). 11453893 PMC2014499
  3. [3]Ceci A Clinical Trials in Paediatrics — Regulatory and Methodological Aspects. in Drug Discovery and Development - From Molecules to Medicine (2015). doi: 10.5772/60611 · DOI
  4. [4]Hwang TJ, Orenstein L, Kesselheim AS & Bourgeois FT Completion Rate and Reporting of Mandatory Pediatric Postmarketing Studies under the US Pediatric Research Equity Act. JAMA Pediatr. 173, 68– 74 (2019). 30452498 PMC6583440
  5. [5]Momper JD, Mulugeta Y & Burckart GJ Failed Pediatric Drug Development Trials. Clin. Pharmacol. Ther 98, 245– 251 (2015). 25963725
  6. [6]Wharton GT Impact of Pediatric Exclusivity on Drug Labeling and Demonstrations of Efficacy. Pediatrics 134, e512– e518 (2014). 25022732
  7. [7]Balan S, Hassali MAA & Mak VSL Two decades of off-label prescribing in children: a literature review. World J. Pediatr 14, 528– 540 (2018). 30218415
  8. [8]Giangreco NP, Elias JE & Tatonetti NP No population left behind: Improving paediatric drug safety using informatics and systems biology. Br. J. Clin. Pharmacol bcp.14705 (2020). doi: 10.1111/bcp.14705 PMC8209126 33332641 · DOI
  9. [9]Hines RN Ontogeny of human hepatic cytochromes P450. J. Biochem. Mol. Toxicol 21, 169– 175 (2007). 17936930
  10. [10]Saghir SA, Khan SA & McCoy AT Ontogeny of mammalian metabolizing enzymes in humans and animals used in toxicological studies. Crit. Rev. Toxicol 42, 323– 357 (2012). 22512665
  11. [11]Redmond GP, Bell JJ & Perel JM Effect of human growth hormone on amobarbital metabolism in children. Clin. Pharmacol. Ther 24, 213– 8 (1978). 679599
  12. [13]Kennedy MJ Hormonal Regulation of Hepatic Drug-Metabolizing Enzyme Activity During Adolescence. Clin. Pharmacol. Ther 84, 662– 673 (2008). 18971926 PMC2684751
  13. [14]van den Anker JN How to Improve the Safe and Effective Use of Doxorubicin in Children with Cancer. Clin. Pharmacokinet 54, 1091– 1093 (2015). 26123706
  14. [15]Solleveld MM, Schrantee A, Puts NAJ, Reneman L & Lucassen PJ Age-dependent, lasting effects of methylphenidate on the GABAergic system of ADHD patients. NeuroImage Clin. 15, 812– 818 (2017). 28725548 PMC5506880
  15. [16]Baldrick P Juvenile animal testing in drug development - Is it useful? Regul. Toxicol. Pharmacol 57, 291– 299 (2010). 20350578
  16. [17]Ren Z & Zajicek A Review of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act: What can the obstetric community learn from the pediatric experience? Semin. Perinatol 39, 530– 531 (2015). 26455383 PMC4634862
  17. [18]Benjamin DK Safety and Transparency of Pediatric Drug Trials. Arch. Pediatr. Adolesc. Med 163, 1080– 1086 (2009). 19996043 PMC2792563
  18. [19]Osokogu OU Drug Safety Monitoring in Children: Performance of Signal Detection Algorithms and Impact of Age Stratification. Drug Saf. 39, 873– 881 (2016). 27255487 PMC4982893
  19. [20]Star K, Norén GN, Nordin K & Edwards IR Suspected adverse drug reactions reported for children worldwide: An exploratory study using vigibase. Drug Saf. 34, 415– 428 (2011). 21513364
  20. [21]Star K Detecting unexpected adverse drug reactions in children. Pediatr. Drugs 13, 71– 73 (2011). 21351806
  21. [22]Sakaeda T, Tamon A, Kadoyama K & Okuno Y Data mining of the public version of the FDA adverse event reporting system. International Journal of Medical Sciences 10, 796– 803 (2013). 23794943 PMC3689877
  22. [23]Tatonetti NPP, Ye PPP, Daneshjou R & Altman RBB Data-driven prediction of drug effects and interactions. Sci. Transl. Med 4, 125ra31– 125ra31 (2012). PMC3382018 22422992
  23. [24]Almenoff JS Novel statistical tools for monitoring the safety of marketed drugs. Clin. Pharmacol. Ther 82, 157– 166 (2007). 17538548
  24. [25]Bate A & Evans SJW Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol. Drug Saf 18, 427– 436 (2009). 19358225
  25. [27]Reinblatt SP, dosReis S, Walkup JT & Riddle MA Activation Adverse Events Induced by the Selective Serotonin Reuptake Inhibitor Fluvoxamine in Children and Adolescents. J. Child Adolesc. Psychopharmacol 19, 119– 126 (2009). 19364290 PMC2856972
  26. [28]Czaja AS Electronic health record (EHR) based postmarketing surveillance of adverse events associated with pediatric off-label medication use: A case study of short-acting beta-2 agonists and arrhythmias. Pharmacoepidemiol. Drug Saf 27, 815– 822 (2018). 29806185
  27. [29]Giangreco NP & Tatonetti NP Evaluating risk detection methods to uncover ontogenic-mediated adverse drug effect mechanisms in children. BioData Min. 2021 141 14, 1– 17 (2021). PMC8296590 34294093
  28. [31]McLaren JD Artificial light at night confounds broad-scale habitat use by migrating birds. Ecol. Lett 21, 356– 364 (2018). 29316091
  29. [32]Osokogu OU Pediatric drug safety signal detection: a new drug-event reference set for performance testing of data-mining methods and systems. Drug Saf. 38, 207– 17 (2015). 25663078 PMC4328124
  30. [34]Wallerstedt SM, Brunlöf G, Sundström A & Eriksson AL Montelukast and psychiatric disorders in children. Pharmacoepidemiol. Drug Saf 18, 858– 64 (2009). 19551697
  31. [35]Bygdell M, Brunlöf G, Wallerstedt SM & Kindblom JM Psychiatric adverse drug reactions reported during a 10-year period in the Swedish pediatric population. Pharmacoepidemiol. Drug Saf 21, 79– 86 (2012). 22076661
  32. [36]Aldea Perona A, García-Sáiz M & Sanz Álvarez E Psychiatric Disorders and Montelukast in Children: A Disproportionality Analysis of the VigiBase®. Drug Saf. 39, 69– 78 (2016). 26620206
  33. [37]Zanger UM & Schwab M Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther 138, 103– 41 (2013). 23333322
  34. [38]Johnson T The development of drug metabolising enzymes and their influence on the susceptibility to adverse drug reactions in children. Toxicology 192, 37– 48 (2003). 14511902
  35. [39]Upreti VV & Wahlstrom JL Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling. J. Clin. Pharmacol 56, 266– 83 (2016). 26139104
  36. [40]Vanstone MB, Oberfield SE, Shader L, Ardeshirpour L & Carpenter TO Hypercalcemia in children receiving pharmacologic doses of vitamin D. Pediatrics 129, (2012). PMC8194455 22412034
  37. [42]Nicolao P & Giometto B Neurological Toxicity of Ifosfamide. Oncology 65, 11– 16 (2003). 14586141
  38. [43]Kilic S Protection from cyclophosphamide-induced ovarian damage with bone marrow-derived mesenchymal stem cells during puberty. Gynecol. Endocrinol 30, 135– 140 (2014). 24308768
  39. [44]Kaufman J, Messazos B, Sharples-blissland N & Cameron F Extreme physiological gynaecomastia in the neonate: Observation not intervention. 51, 1030– 1032 (2015). 25940908
  40. [45]Kass-Hout TA OpenFDA: An innovative platform providing access to a wealth of FDA’s publicly available data. J. Am. Med. Informatics Assoc 23, 596– 600 (2016). PMC4901374 26644398
  41. [46]Williams K Standard 6: Age groups for pediatric trials. Pediatrics 129, S153– S160 (2012). 22661762
  42. [48]Wishart DS DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 34, 668– 672 (2006). PMC1347430 16381955
  43. [50]Hastie T & Tibshirani R Generalized additive models for medical research. Stat. Methods Med. Res 4, 187– 196 (1995). 8548102
  44. [51]Wood SN Generalized additive models: An introduction with R, second edition. Generalized Additive Models: An Introduction with R, Second Edition (2017). doi: 10.1201/9781315370279 · DOI · Paper page
  45. [53]Sardá-Espinosa A Time-Series Clustering in R Using the dtwclust Package. R J. 11, 22 (2019).
  46. [54]Paparrizos J & Gravano L K-shape: Efficient and accurate clustering of time series. Proc. ACM SIGMOD Int. Conf. Manag. Data 2015-May, 1855– 1870 (2015).
  47. [55]Cuturi M Fast global alignment kernels. Proc. 28th Int. Conf. Mach. Learn. ICML 2011 929– 936 (2011).
  48. [56]Crespi B The evolutionary biology of child health. Proc. R. Soc. B Biol. Sci 278, 1441– 1449 (2011). PMC3081756 21288946
  49. [57]Gunewardena SS Deciphering the Developmental Dynamics of the Mouse Liver Transcriptome. PLoS One 10, e0141220 (2015). 26496202 PMC4619800
  50. [58]Kuhn M, Letunic I, Jensen LJ & Bork P The SIDER database of drugs and side effects. 44, 1075– 1079 (2016). PMC4702794 26481350

Cited by

Sorted by citations

Authors
Giangreco, N. P., & Tatonetti, N. P.
Affiliations
Columbia University (US)
Corresponding author
Tatonetti, Nicholas P.
ORCID
Venue
Med
Publisher
Elsevier BV
Published
2022-08
Volume
3
Issue
8
Pages
579-595.e7
ISSN
2666-6340 (ISSN-L)
DOI
10.1016/j.medj.2022.06.001
PMC
PMC9378670
OpenAlex
W4283398051
Cited by
16
References
1
Citations by year
2026: 6 · 2025: 7 · 2024: 3
FWCI
1.88
Type
journal article
Language
en
Open access
Licence
Locations
  • Med (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (R01GM107145, U54CA209997)
  • National Library of Medicine
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Health Sciences › Medicine › Epidemiology › Data-Driven Disease Surveillance
  • Health Sciences › Medicine › Complementary and alternative medicine › Complementary and Alternative Medicine Studies
Keywords
drug safety signals, child growth and development, drug metabolism genes, CYP2C18, CYP27B1, montelukast, mental illness, post-marketing surveillance, adverse event reports
MeSH terms
Child, Family, Humans, Databases, Factual, Adverse Drug Reaction Reporting Systems, Growth and Development, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review